Literature DB >> 23077721

Nonoisotopic assay for the presynaptic choline transporter reveals capacity for allosteric modulation of choline uptake.

Alicia M Ruggiero1, Jane Wright, Shawn M Ferguson, Michelle Lewis, Katie S Emerson, Hideki Iwamoto, Michael T Ivy, Ericka C Holmstrand, Elizabeth A Ennis, C David Weaver, Randy D Blakely.   

Abstract

Current therapies to enhance CNS cholinergic function rely primarily on extracellular acetylcholinesterase (AChE) inhibition, a pharmacotherapeutic strategy that produces dose-limiting side effects. The Na(+)-dependent, high-affinity choline transporter (CHT) is an unexplored target for cholinergic medication development. Although functional at the plasma membrane, CHT at steady-state is localized to synaptic vesicles such that vesicular fusion can support a biosynthetic response to neuronal excitation. To identify allosteric potentiators of CHT activity, we mapped endocytic sequences in the C-terminus of human CHT, identifying transporter mutants that exhibit significantly increased transport function. A stable HEK-293 cell line was generated from one of these mutants (CHT LV-AA) and used to establish a high-throughput screen (HTS) compatible assay based on the electrogenic nature of the transporter. We established that the addition of choline to these cells, at concentrations appropriate for high-affinity choline transport at presynaptic terminals, generates a hemicholinium-3 (HC-3)-sensitive, membrane depolarization that can be used for the screening of CHT inhibitors and activators. Using this assay, we discovered that staurosporine increased CHT LV-AA choline uptake activity, an effect mediated by a decrease in choline K(M) with no change in V(max). As staurosporine did not change surface levels of CHT, nor inhibit HC-3 binding, we propose that its action is directly or indirectly allosteric in nature. Surprisingly, staurosporine reduced choline-induced membrane depolarization, suggesting that increased substrate coupling to ion gradients, arising at the expense of nonstoichiometric ion flow, accompanies a shift of CHT to a higher-affinity state. Our findings provide a new approach for the identification of CHT modulators that is compatible with high-throughput screening approaches and presents a novel model by which small molecules can enhance substrate flux through enhanced gradient coupling.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23077721      PMCID: PMC3474274          DOI: 10.1021/cn3000718

Source DB:  PubMed          Journal:  ACS Chem Neurosci        ISSN: 1948-7193            Impact factor:   4.418


  68 in total

Review 1.  Alzheimer's disease pathogenesis and therapeutic interventions.

Authors:  M S Parihar; Taruna Hemnani
Journal:  J Clin Neurosci       Date:  2004-06       Impact factor: 1.961

Review 2.  Modulation of neurotransmitter release by the second messenger-activated protein kinases: implications for presynaptic plasticity.

Authors:  A G Miriam Leenders; Zu-Hang Sheng
Journal:  Pharmacol Ther       Date:  2005-01       Impact factor: 12.310

3.  Molecular cloning and characterization of a murine hemicholinium-3-sensitive choline transporter.

Authors:  S Apparsundaram; S M Ferguson; R D Blakely
Journal:  Biochem Soc Trans       Date:  2001-11       Impact factor: 5.407

4.  A phosphorylation site regulates sorting of the vesicular acetylcholine transporter to dense core vesicles.

Authors:  D E Krantz; C Waites; V Oorschot; Y Liu; R I Wilson; P K Tan; J Klumperman; R H Edwards
Journal:  J Cell Biol       Date:  2000-04-17       Impact factor: 10.539

5.  Do cholinergic therapies have disease-modifying effects in Alzheimer's disease?

Authors:  Marwan N Sabbagh; Martin R Farlow; Normal Relkin; Thomas G Beach
Journal:  Alzheimers Dement       Date:  2006-04       Impact factor: 21.566

Review 6.  Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders.

Authors:  P Jeffrey Conn; Carrie K Jones; Craig W Lindsley
Journal:  Trends Pharmacol Sci       Date:  2009-02-07       Impact factor: 14.819

7.  Aberrant trafficking of the high-affinity choline transporter in AP-3-deficient mice.

Authors:  Hidemi Misawa; Hirofumi Fujigaya; Takashi Nishimura; Yasuhiro Moriwaki; Takashi Okuda; Koichiro Kawashima; Kazuko Nakata; Alicia M Ruggiero; Randy D Blakely; Fubito Nakatsu; Hiroshi Ohno
Journal:  Eur J Neurosci       Date:  2008-06-01       Impact factor: 3.386

8.  Choline: high-affinity uptake by rat brain synaptosomes.

Authors:  H I Yamamura; S H Snyder
Journal:  Science       Date:  1972-11-10       Impact factor: 47.728

9.  Characterization of [3H]hemicholinium-3 binding associated with neuronal choline uptake sites in rat brain membranes.

Authors:  K Sandberg; J T Coyle
Journal:  Brain Res       Date:  1985-12-02       Impact factor: 3.252

10.  Myasthenia gravis: a review of available treatment approaches.

Authors:  Nils Erik Gilhus; Jone F Owe; Jana Midelfart Hoff; Fredrik Romi; Geir Olve Skeie; Johan A Aarli
Journal:  Autoimmune Dis       Date:  2011-10-05
View more
  11 in total

1.  Differential impact of genetically modulated choline transporter expression on the release of endogenous versus newly synthesized acetylcholine.

Authors:  Hideki Iwamoto; M Wade Calcutt; Randy D Blakely
Journal:  Neurochem Int       Date:  2016-03-22       Impact factor: 3.921

Review 2.  Importing, caring, breeding, genotyping, and phenotyping a genetic mouse in a Chinese university.

Authors:  S T Kuo; Q H Wu; B Liu; Z L Xie; X Wu; S J Shang; X Y Zhang; X J Kang; L N Liu; F P Zhu; Y S Wang; M Q Hu; H D Xu; L Zhou; B Liu; Z Y Chai; Q F Zhang; W Liu; S S Teng; C H Wang; N Guo; H Q Dou; P L Zuo; L H Zheng; C X Zhang; D S Zhu; L Wang; S R Wang; Z Zhou
Journal:  J Mol Neurosci       Date:  2014-01-03       Impact factor: 3.444

3.  Synthesis and structure-activity relationships of a series of 4-methoxy-3-(piperidin-4-yl)oxy benzamides as novel inhibitors of the presynaptic choline transporter.

Authors:  Sean R Bollinger; Darren W Engers; Elizabeth A Ennis; Jane Wright; Charles W Locuson; Craig W Lindsley; Randy D Blakely; Corey R Hopkins
Journal:  Bioorg Med Chem Lett       Date:  2015-02-28       Impact factor: 2.823

4.  Identification of novel inhibitors of the amino acid transporter B0 AT1 (SLC6A19), a potential target to induce protein restriction and to treat type 2 diabetes.

Authors:  Qi Cheng; Nishank Shah; Angelika Bröer; Stephen Fairweather; Yang Jiang; Dieter Schmoll; Ben Corry; Stefan Bröer
Journal:  Br J Pharmacol       Date:  2017-02-14       Impact factor: 8.739

5.  The presynaptic choline transporter imposes limits on sustained cortical acetylcholine release and attention.

Authors:  Vinay Parikh; Megan St Peters; Randy D Blakely; Martin Sarter
Journal:  J Neurosci       Date:  2013-02-06       Impact factor: 6.167

6.  Transgenic overexpression of the presynaptic choline transporter elevates acetylcholine levels and augments motor endurance.

Authors:  Ericka C Holmstrand; David Lund; Ajeesh Koshy Cherian; Jane Wright; Rolicia F Martin; Elizabeth A Ennis; Gregg D Stanwood; Martin Sarter; Randy D Blakely
Journal:  Neurochem Int       Date:  2013-11-22       Impact factor: 3.921

7.  Insulin Regulates the Activity of the High-Affinity Choline Transporter CHT.

Authors:  Katherine J Fishwick; R Jane Rylett
Journal:  PLoS One       Date:  2015-07-10       Impact factor: 3.240

8.  Identification and characterization of ML352: a novel, noncompetitive inhibitor of the presynaptic choline transporter.

Authors:  Elizabeth A Ennis; Jane Wright; Cassandra L Retzlaff; Owen B McManus; Zhinong Lin; Xiaofang Huang; Meng Wu; Min Li; J Scott Daniels; Craig W Lindsley; Corey R Hopkins; Randy D Blakely
Journal:  ACS Chem Neurosci       Date:  2015-02-02       Impact factor: 4.418

9.  Discovery of Compounds that Positively Modulate the High Affinity Choline Transporter.

Authors:  Parul Choudhary; Emma J Armstrong; Csilla C Jorgensen; Mary Piotrowski; Maria Barthmes; Rubben Torella; Sarah E Johnston; Yuya Maruyama; John S Janiszewski; R Ian Storer; Sarah E Skerratt; Caroline L Benn
Journal:  Front Mol Neurosci       Date:  2017-02-27       Impact factor: 5.639

10.  Truncating SLC5A7 mutations underlie a spectrum of dominant hereditary motor neuropathies.

Authors:  Claire G Salter; Danique Beijer; Holly Hardy; Katy E S Barwick; Matthew Bower; Ines Mademan; Peter De Jonghe; Tine Deconinck; Mark A Russell; Meriel M McEntagart; Barry A Chioza; Randy D Blakely; John K Chilton; Jan De Bleecker; Jonathan Baets; Emma L Baple; David Walk; Andrew H Crosby
Journal:  Neurol Genet       Date:  2018-03-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.